Fructoselysine 3-phosphate is synthesized in vivo by the recently discovered fructoseamine-3-kinase (F3K) from fructoselysine and ATP and decomposes to lysine, P i and 3-deoxyglucosone (3DG). This pathway appears to dominate 3DG production in vivo, making it possible to modulate 3DG levels by stimulating or inhibiting the reaction. Present inhibitors are non-reacting substrate analogues with relatively high K i values and can inhibit F3K sufficiently in vivo to reduce 3DG in diabetic rat plasma by approx. 50%. Stimulation of the F3K pathway by feeding glycated casein causes an increase of 10-20-fold in plasma levels of 3DG and 3-fold in kidney tubules. Consequences of this increase were studied in two systems: the Eker rat, a model of susceptible kidney tubules; and birth rates in two rat strains. In both cases substantial pathological effects were observed. In the Eker rats, an approx. 3-fold increase in kidney lesions was observed (P < 0.00001). In both Fischer 344 and Sprague-Dawley rats, birth rates were reduced by 56% (P < 0.0001) and 12% (P < 0.015) respectively. These results suggest that inhibition of F3K is a promising new therapeutic target for diabetic complications, as well as other 3DG-dependent pathologies.
Introduction
Glycation of lysine by glucose was first described by Maillard [1] . In this reaction the -amino group of lysine condenses with the carbonyl on glucose to form a Schiff's base, which rearranges to a carbonyl at C2 of glucose to produce the modified amino acid, fructoselysine (FL). This reaction has been studied for many years, since it is the primary route of lysine loss in heated milk products [2] . FL was thought not to be metabolized in mammals until the recent discovery of a phosphorylated derivative of FL, FL 3-phosphate (FL3P), showed otherwise [3] . The enzyme responsible was isolated and sequenced from human red cells by Delpierre et al. [4] . It has been found in rats, mice, chickens, pigs and rabbits. The reaction phosphorylates the three position of FL, or other fructoseamines, using ATP as a phosphate donor. The enzyme's likely function is to act as a lysine recovery pathway, by recovery of lysine from FL3P on or off protein.
FL3P spontaneously decomposes with a lifetime of approx. 6 h under standard physiological conditions to yield lysine, inorganic phosphate (P i ) and the reactive dicarbonyl 3-deoxyglucosone (3DG), an early component in the formation of advanced glycation end-products (AGEs) [5] . Non-enzymatic glycation, during which reducing sugars covalently attach to free amino groups and ultimately proceed to form AGEs, occurs during normal aging and at an accelerated rate in diabetes mellitus [6] . This process changes irreversibly the structural and functional properties of proteins, lipid components and nucleic acids [6] . Its acceleration Key words: Abbreviations used: F3K, fructoseamine-3-kinase; 3DG, 3-deoxyglucosone; FL, fructoselysine; FL3P, FL 3-phosphate; AGE, advanced glycation end-product; Cbz, benzyloxycarbonyl; 3DF, 3-deoxyfructose. 1 To whom correspondence should be addressed (e-mail trb11@columbia.edu).
has been postulated to contribute to the development of diabetic complications including nephropathy, retinopathy and neuropathy [7] . AGE inhibitors prevent and/or reverse endothelial cell proliferation [8] , and inhibition of AGE formation reduces the extent of nephropathy in diabetic rats [9] .
3DG plays a key role in this process [10] [11] [12] . Plasma levels of 3DG in a diabetic population suggested a causal connection to microangiopathy, retinopathy and neuropathy [13] . Whether this is due to the direct action of 3DG on proteins or its more indirect role in raising AGE levels is unknown. In any case, higher plasma levels of 3DG are significantly associated with pathology. Until the discovery of fructoseamine-3-kinase (F3K), in vivo 3DG was believed to result entirely from non-enzymatic processes involving FL-containing protein [14, 15] . Measurements in tissue extracts, in vitro solutions and estimates of 3DG production in vivo indicate that levels of F3K-produced 3DG are 20-fold higher than those of non-enzymatically produced 3DG. Thus, by stimulating or inhibiting F3K, we can modulate in vivo 3DG levels. In this paper, we review the pathological consequences of stimulating the F3K pathway through dietary manipulation and the changes in 3DG levels in vivo due to inhibition of the reaction. 
Materials and methods

Animals
Synthesis of 3-O-methylsorbitol-lysine
3-O-Methylglucose (25 g, 129 mmol) and α-Cbz (benzyloxycarbonyl)-lysine (12 g, 43 mmol) were dissolved in 200 ml of water/methanol (2:1, v/v). Sodium cyanoborohydride (10 g, 162 mmol) was added and the reaction was stirred at room temperature. Reaction of α-Cbz-lysine was monitored by TLC on a silica gel employing 1-butanol/acetic acid/water (5/2/3, by vol.) using ninhydrin for visualization. The reaction was complete when no α-Cbz-lysine remained. The solution was neutralized with 3 M acetic acid and then applied to a column (5 cm × 50 cm) of Dowex-50 (H+) and the column was washed well with water to remove excess 3-O-methylglucose. The target compound was eluted with 5% ammonium hydroxide. After evaporation the residue was dissolved in 50 ml of water/methanol (2:1, v/v) and 10% Pd/C (0.5 g) was added. The mixture was shaken under 20 lbf/in 2 of hydrogen for 1 h. The charcoal was filtered off and the filtrate evaporated to a white powder (10.7 g, 77% yield based on α-Cbz-lysine) that was homogeneous when analysed by reversed-phase HPLC as the phenylisothiocyanate derivative. Elemental analysis: calculated for C 13 
Enzyme isolation
Samples (100 g) of chicken kidney were homogenized in 300 ml of 10 mM Tricine, pH 7.4, and centrifuged at 4000 g for 0.5 h; the supernatant was then centrifuged at 100 000 g for 1 h. The clear supernatant was brought to 30% saturation with solid ammonium sulphate, stirred at 0
• C for 0.5 h, centrifuged and the pellet was discarded. The solution was brought to 60% saturation with ammonium sulphate. After 0.5 h at 0
• C, the precipitate was collected and dissolved in the minimum volume of 10 mM Tricine, pH 7.0, and dialysed against the same buffer containing 1 mM dithiothreitol, 0.02 mM EDTA, 1 mg/l antipain and 1 mg/l leupeptin. The sample was applied to a CM52 cellulose column (2.5 cm × 20 cm) equilibrated with dialysis buffer, pH 8.0, and washed with three column-volumes of the same buffer. The column was developed with a linear gradient of 0-400 mM KCl/ 1 mM ATP. The active fractions were pooled, diluted with buffer to approximately 25 mM KCl and applied to a column of Cibachron Blue 3GA (1.5 cm × 40 cm) equilibrated in 25 mM Hepes, pH 7.4. The column was washed with 100 ml of the equilibration buffer and developed with a linear gradient of 0-500 mM KCl in the same buffer. The active fractions were pooled, concentrated and dialysed against 25 mM Hepes, pH 7.4, and then chromatofocused on a column of PBE 118 (1 cm × 40 cm) equilibrated with 25 mM triethylamine, pH 11. The column was developed with Pharmalyte, pH 8-10.5, adjusted to pH 8.0 with HCl. The active fractions were pooled, Tween 20 added to 0.1% (v/v), concentrated and chromatographed on a SMART system, employing Superdex 200 equilibrated in 25 mM Hepes, pH 7.4. SDS/PAGE of the individual active fractions normally has at least one fraction as a single protein.
The kinase has a molecular mass of approx. 35 000 Da. The highest activity fraction from Superdex had a specific activity of 8 µmol/min per mg of protein. This represented a 40 000-fold purification from the crude homogenate.
Measurement of 3DG/3-deoxyfructose (3DF)
3DG and 3DF were analysed as described previously [13] .
Feeding experiments
All feeding experiments compared a control diet with a glycated diet. Both diets were supplied by Dyets, Inc. (Bethlehem, PA, U.S.A.) and consisted of their standard rat chow (AIN-93G) to which 5% (w/w) of a casein/glucose mixture (1:2, w/w) was added. For both diets, the casein and glucose were heated at 60
• C for 70 h, together in a paste for the glycerated diet and separately for the control diet. In the glycerated diet, the lysine residues of the casein are converted into FL by this procedure. As the casein is digested, these become available as free FL, which is phosphorylated intracellularly by F3K.
Results
The consequences of stimulating the F3K pathway were investigated in two model systems. Stimulation of the F3K pathway is relatively easy; simply feeding a diet rich in FL residues created by heating glucose and casein together dramatically increases 3DG levels. Preliminary experiments showed that 5% (w/w) of this mildly glycated casein in a standard diet stimulated 3DG levels 10-20-fold in the plasma and approx. 3 fold in the kidney compared with a control diet containing identical constituents, except that the glucose and casein were heated separately and thus did not form FL. For example, the levels of FL, 3DG and its major detoxification product 3DF in kidney tubules and glomeruli after 3 days on the glycated diet increased the levels of FL in both compartments approx. 3 fold. 3DG and 3DF were elevated only in the tubules. Furthermore, their levels increased approximately proportionally with the increase in tubular FL levels.
Since kidney tubules show increased 3DG levels a natural choice of a model system is one in which insults to the kidney result in enhanced tubular lesions. The Eker rat is well known to be susceptible in this way [17, 18] . The susceptibility is due to the Tsc2 gene, similar to that found in humans [19] . This gene was placed in a Fischer 344 background by Dr Yeung of the University of Washington (Seattle, WA, U.S.A.) who kindly supplied us with several male carriers. These were bred to wild-type Fischer 344 females and the F1 pups were identified by genotyping tail clips. These animals show a phenotype of kidney lesions and tumours [20] . They are thus an excellent model to investigate the effects of increasing 3DG levels in the kidney on the development of pathology. Two cohorts of rats carrying the Eker mutation were placed ad lib for 12 weeks on the control diet and the glycerated diet respectively, and subsequently killed. Their kidneys were fixed and sectioned for histopathology. The sections were analysed blindly by Dr Klein-Santo of the Fox Chase Cancer Center (Philadelphia, PA, U.S.A.) who scored each section for lesions [18] . Comparison of the two cohorts is presented in Table 1 . The glycerated diet increased the number of kidney lesions approx. 3-fold. Lesion counts in both diets showed both statistical distributions to be Poisson, with the mean for the glycerated diet nearly 3 times larger than for the control diet (P < 0.00001). Recent work has also implicated 3DG in the aetiology of diabetic embryopathy, suggesting that elevation of 3DG may increase developmental abnormalities [21] . To test this, relative birth rates of cohorts with ad lib access to the control diet and the glycerated diet were compared. Two cohorts of Fischer 344 rats consisting of six breeding pairs each were placed on each diet for 10 months and the number of live pups produced recorded. Over this period the cohort on the control diet gave birth to 295 pups compared with 131 for the cohort on the glycerated diet. The time course is shown in Figure 1 . Litter sizes were not significantly different in the two cohorts (6.4 compared with 5.7 respectively), but the number of litters in the cohort on the glycated diet was significantly less (23 compared with 46). Assuming Poisson statistics for the litters, P < 0.0001. The experiment was repeated with two cohorts of six pairs of Sprague-Dawley rats. After 9 months, the cohort on the glycerated diet gave birth to 456 pups compared with 516 for the cohort on the control diet. Again, the litter sizes were similar, but the litter number was significantly less for the cohort on the glycated diet (47 compared with 59; P = 0.015).
Inhibitors that were FL analogues, such as morpholino fructose, were successful in blocking the formation of FL3P in vitro. Unfortunately, these compounds are also substrates for F3K, and the resulting products also decompose to 3DG, making them unsuitable for use in vivo. Inhibitors based on sorbitol, on the other hand, show competitive inhibition of the F3K reaction but also prevent the formation of 3DG, because there is no spontaneous decomposition of the product to 3DG. For compounds blocked at C3, also there is no product formed. The K i values of these compounds are approx. 500 µM. Although high for an in vivo drug, their apparent low toxicity make it possible to use them, at least in animals, to lower 3DG levels.
These inhibitors were tested in diabetic rats. Of the four cohorts in the experiment two were made diabetic by intraperitoneal injection of streptozotocin (60 mg/kg). After 3 days any animal with blood glucose less than 300 mg/dl was removed from the experiment, leaving six rats in each diabetic cohort. One control and one diabetic cohort were injected intraperitoneally daily with 3-O-methylsorbitollysine (50 mg/kg) or saline for a period of 6 days. The animals were then killed and blood was obtained by cardiac puncture. As can be seen in Table 2 , both control and diabetic animals showed an approx, 50% reduction in 3DG levels. This is the first report of reduction in 3DG levels in the plasma of diabetic animals by therapeutic intervention, although 3DG levels in erythrocytes have been reduced using aldose reductase inhibitors [22] .
Discussion
Using the F3K pathway, 3DG levels in vivo can be manipulated in a controlled way. Our preliminary experiments demonstrate that is possible to reduce 3DG levels in vivo although our present inhibitors are not ideal, since they have high K i values and dosages in the mg/kg range are needed to inhibit F3K [23] . Because of this, we are unable to conclusively confirm 3DG's role in diabetic and other pathologies by lowering its level for extended periods. Nevertheless, the experiments have proven that at least 50% of 3DG in vivo comes from the F3K reaction. The apparently linear relationship observed between FL and 3DG levels in the kidney tubules of rats suggests that inhibiting F3K more effectively could reduce 3DG levels further. An alternative approach is to stimulate the flux in the F3K pathway, thereby increasing 3DG levels. Several points should be made regarding this class of experiments. First, the consequences of the stimulation are observed against a control diet made up of the same constituents but heated separately to prevent the formation of glycated residues. Since the heating was very mild (60
• C for 70 h) and the same for both diets, we have been unable to conceive of a mechanism other than the elevation of 3DG as the cause of the pathological sequalae. Secondly, the intracellular levels of 3DG almost certainly will be distributed differently from those found in hyperglycaemia because they will depend on how the glycated amino acid, FL, is distributed following absorption after casein digestion. In hyperglycaemia, either the lysine is deglycated by F3K while on the protein, or the protein is recycled within the cell. We do not know how much of the resultant FL is released into the plasma and available systemically. Finally, 3DG produced by the F3K pathway will be different than 3DG directly fed to an animal for several reasons: (1) dietary 3DG can react in the gut with other amines and be detoxified; (2) 3DG created intracellularly is able to interact directly with protein and DNA without needing to be transported; and (3) the conformations of newly synthesized 3DG will be different from the equilibrium distribution of conformers. This latter is important, as the reactive form of a carbonyl is the unhydrated open chain form. This is always low at equilibrium, whereas it could be high immediately following FL3P decomposition.
It is clear from Table 1 that Eker rats are sensitive to the glycerated diet, increasing their number of kidney lesions almost 3-fold. Comparing this with the approx. 3-fold increase in 3DG observed in the tubules of normal rats on the same diet suggests that the dose-response relationship is in the correct range for 3DG to be a significant agent in stimulating kidney lesion formation in these susceptible rats. It is impossible to know whether the mechanism is direct adduct formation on DNA, excess production of various growth factors by 3DG [24] , or some other effect. Further work is needed to confirm these observations and identify the causal pathway.
Since 3DG is known to cause embryopathy the birth rate reductions for animals on the glycerated diet are very compelling. Because there are many factors which affect an animal's birth rate (season, lighting, handling, etc.), they were located in the same room, handled and cared for by the same staff in an attempt to minimize all influences other than the diet. Although elevation of 3DG appears responsible for the birth rate decline, the precise mechanism is unknown. It may be a problem in the pup development, but sperm viability in the fathers or other effects of 3DG in the mothers cannot be excluded.
In summary, our experiments strongly suggest that 3DG produced as a consequence of the formation of FL3P by the F3K pathway is a significant contributor to a wide range of pathological sequalae. Observations of increased pathology following stimulation of the pathway by feeding a glycated diet are powerful, but not conclusive indicators of this. To demonstrate conclusive causality we must be able to inhibit the pathway successfully in vivo. Thus far, we have been able to reduce 3DG levels by 50%, although higher reduction may be possible with our present inhibitors, since there were no signs of toxicity at the dosages used. Our results show this reaction to be a new potential therapeutic target for diabetic complications as well as other 3DG-dependent pathologies.
